Kamiya A, Inokuchi M, Otsuki S, Sugita H, Kato K, Uetake H, Sugihara K, Takagi Y, Kojima K
Department of Surgical Oncology, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Department of Translational Oncology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan.
Clin Transl Oncol. 2016 Jun;18(6):599-607. doi: 10.1007/s12094-015-1407-7. Epub 2015 Oct 12.
Tropomyosin-related kinase (Trk) receptors play critical roles in tumor development and are considered attractive targets for cancer therapy. We investigated correlations of the expression of TrkA, TrkB, and TrkC with clinicopathological features and outcomes in gastric cancer.
Tumor samples were obtained from 221 patients with gastric cancer who underwent gastrectomy between 2003 and 2007. The expression of TrkA, TrkB, and TrkC was analyzed using immunohistochemical staining. The relationship of their expression to clinicopathological factors and outcomes was assessed.
High expression of TrkA, TrkB, or TrkC was significantly associated with histopathology (p = 0.022, p < 0.001, and p < 0.001). High expression of TrkA was significantly correlated with variables related to tumor progression, including lymph node metastasis (p = 0.024) and distant metastasis or recurrence (p < 0.001). Distant metastasis or recurrence was found in a significantly higher proportion of patients with high expression of TrkC than in those with low expression (p = 0.036). High expression of TrkA was significantly associated with poorer relapse-free survival (RFS) in univariate analysis (p = 0.001). High expression of TrkA or TrkC was significantly associated with poorer disease-specific survival (DSS) in univariate analysis (p < 0.001 and p = 0.008). In multivariate analysis, TrkA was an independent predictor of RFS [hazard ratio (HR), 2.294; 95 % confidence interval (CI), 1.309-4.032; p = 0.004] and DSS (HR, 2.146; 95 % CI, 1.195-3.861; p = 0.011). Expression of TrkB was not associated with RFS or DSS in univariate analysis.
Our results demonstrated that TrkA expression was associated with tumor progression and poor survival, and was an independent predictor of poor outcomes in gastric cancer patients.
原肌球蛋白相关激酶(Trk)受体在肿瘤发展中起关键作用,被认为是癌症治疗的有吸引力的靶点。我们研究了TrkA、TrkB和TrkC的表达与胃癌临床病理特征及预后的相关性。
从2003年至2007年间接受胃切除术的221例胃癌患者中获取肿瘤样本。采用免疫组织化学染色分析TrkA、TrkB和TrkC的表达。评估它们的表达与临床病理因素及预后的关系。
TrkA、TrkB或TrkC的高表达与组织病理学显著相关(p = 0.022、p < 0.001和p < 0.001)。TrkA的高表达与肿瘤进展相关变量显著相关,包括淋巴结转移(p = 0.024)和远处转移或复发(p < 0.001)。TrkC高表达患者的远处转移或复发比例显著高于低表达患者(p = 0.036)。在单因素分析中,TrkA的高表达与无复发生存期(RFS)较差显著相关(p = 0.001)。在单因素分析中,TrkA或TrkC的高表达与疾病特异性生存期(DSS)较差显著相关(p < 0.001和p = 0.008)。在多因素分析中,TrkA是RFS的独立预测因子[风险比(HR),2.294;95%置信区间(CI),1.309 - 4.032;p = 0.004]和DSS的独立预测因子(HR,2.146;95%CI,1.195 - 3.861;p = 0.011)。在单因素分析中,TrkB的表达与RFS或DSS无关。
我们的结果表明,TrkA表达与肿瘤进展和不良生存相关,是胃癌患者不良预后的独立预测因子。